Compare Novartis AG (NVS) vs Procter & Gamble Co (PG) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.

PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.